Get In Touch with Cell BioEngines
Please tell us a little bit about yourself and why you'd like to get connected. Cell BioEngines + SOSV will follow up with you via email.
Discovery of CAR-T cell-based therapies has transformed the treatment landscape for blood cancer patients. Still, the process to achieve this is “one patient – one batch”, limiting manufacturing scalability with high patient-to-patient variability. Moreover, complicated supply chain issues and associated high cost add to the hurdles of providing access to a larger population. On the other hand, the final product is often a non-specific mixed bag of cell states inhibiting its overall functional potency and durability, particularly when providing treatments for solid cancers. As a clinical-stage biotech company, Cell BioEngines is addressing these bottlenecks by utilizing healthy umbilical cord blood as a single stable source, high quality raw material to obtain ‘off-the-shelf’ true stem cells. Their first clinical-stage product is an expanded hematopoietic stem cell therapy to use as a replacement tissue in bone marrow transplantation. Their proprietary manufacturing platform technology, Stem-SPACE, allows Cell BioEngines to also produce a broad arsenal of rare, highly potent clinical-grade immune cells for dosing 10’s and 100’s of patients from 1 cord blood unit at 10X lower cost. Their lead pre-clinical-stage immune cell product is a one-size-fits-all yet personalized cell-based therapeutic vaccine, composed of allogeneic dendritic cell type 1 (cDC1).
Please tell us a little bit about yourself and why you'd like to get connected. Cell BioEngines + SOSV will follow up with you via email.
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.